Determination of Regulatory Review Period for Purposes of Patent Extension; QUVIVIQ, 77868-77870 [2024-21836]
Download as PDF
<![CDATA[
77868
Federal Register / Vol. 89, No. 185 / Tuesday, September 24, 2024 / Notices
lotter on DSK11XQN23PROD with NOTICES1
actual amount of extension that the
Director of USPTO may award (for
example, half the testing phase must be
subtracted as well as any time that may
have occurred before the patent was
issued), FDA’s determination of the
length of a regulatory review period for
a human drug product will include all
of the testing phase and approval phase
as specified in 35 U.S.C. 156(g)(1)(B).
FDA has approved for marketing the
human drug product, OJJAARA
(momelotinib). OJJAARA is indicated
for the treatment of intermediate or
high-risk myelofibrosis (MF), including
primary MF or secondary MF [postpolycythemia vera and post-essential
thrombocythemia], in adults with
anemia. Subsequent to this approval,
the USPTO received patent term
restoration applications for OJJAARA
(U.S. Patent Nos. 8,486,941 and
RE48,285) from GlaxoSmithKline LLC,
and the USPTO requested FDA’s
assistance in determining the patents’
eligibility for patent term restoration. In
a letter dated January 30, 2024, FDA
advised the USPTO that this human
drug product had undergone a
regulatory review period and that the
approval of OJJAARA represented the
first permitted commercial marketing or
use of the product. Thereafter, the
USPTO requested that FDA determine
the product’s regulatory review period.
II. Determination of Regulatory Review
Period
FDA has determined that the
applicable regulatory review period for
OJJAARA is 5,127 days. Of this time,
4,670 days occurred during the testing
phase of the regulatory review period,
while 457 days occurred during the
approval phase. These periods of time
were derived from the following dates:
1. The date an exemption under
section 505(i) of the Federal Food, Drug,
and Cosmetic Act (FD&C Act) (21 U.S.C.
355(i)) became effective: September 3,
2009. FDA has verified the applicant’s
claim that the date the investigational
new drug application became effective
was on September 3, 2009.
2. The date the application was
initially submitted with respect to the
human drug product under section 505
of the FD&C Act: June 16, 2022. FDA
has verified the applicant’s claim that
the new drug application (NDA) for
OJJAARA (NDA 216873) was initially
submitted on June 16, 2022.
3. The date the application was
approved: September 15, 2023. FDA has
verified the applicant’s claim that NDA
216873 was approved on September 15,
2023.
This determination of the regulatory
review period establishes the maximum
VerDate Sep<11>2014
18:07 Sep 23, 2024
Jkt 262001
potential length of a patent extension.
However, the USPTO applies several
statutory limitations in its calculations
of the actual period for patent extension.
In its applications for patent extension,
this applicant seeks 828 days or 5 years
of patent term extension.
III. Petitions
Anyone with knowledge that any of
the dates as published are incorrect may
submit either electronic or written
comments and, under 21 CFR 60.24, ask
for a redetermination (see DATES).
Furthermore, as specified in § 60.30 (21
CFR 60.30), any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period. To
meet its burden, the petition must
comply with all the requirements of
§ 60.30, including but not limited to:
must be timely (see DATES), must be
filed in accordance with § 10.20, must
contain sufficient facts to merit an FDA
investigation, and must certify that a
true and complete copy of the petition
has been served upon the patent
applicant. (See H. Rept. 857, part 1, 98th
Cong., 2d sess., pp. 41–42, 1984.)
Petitions should be in the format
specified in 21 CFR 10.30.
Submit petitions electronically to
https://www.regulations.gov at Docket
No. FDA–2013–S–0610. Submit written
petitions (two copies are required) to the
Dockets Management Staff (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD
20852.
Dated: September 18, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–21844 Filed 9–23–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–E–2584]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; QUVIVIQ
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or the Agency) has
determined the regulatory review period
for QUVIVIQ and is publishing this
notice of that determination as required
by law. FDA has made the
determination because of the
SUMMARY:
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
submission of an application to the
Director of the U.S. Patent and
Trademark Office (USPTO), Department
of Commerce, for the extension of a
patent which claims that human drug
product.
Anyone with knowledge that any
of the dates as published (see
SUPPLEMENTARY INFORMATION) are
incorrect may submit either electronic
or written comments and ask for a
redetermination by November 25, 2024.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
March 24, 2025. See ‘‘Petitions’’ in the
SUPPLEMENTARY INFORMATION section for
more information.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. The https://
www.regulations.gov electronic filing
system will accept comments until
11:59 p.m. Eastern Time at the end of
November 25, 2024. Comments received
by mail/hand delivery/courier (for
written/paper submissions) will be
considered timely if they are received
on or before that date.
DATES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
E:\FR\FM\24SEN1.SGM
24SEN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 185 / Tuesday, September 24, 2024 / Notices
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2023–E–2584 for ‘‘Determination of
Regulatory Review Period for Purposes
of Patent Extension; QUVIVIQ.’’
Received comments, those filed in a
timely manner (see ADDRESSES), will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with § 10.20 (21
CFR 10.20) and other applicable
disclosure law. For more information
about FDA’s posting of comments to
public dockets, see 80 FR 56469,
September 18, 2015, or access the
information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
VerDate Sep<11>2014
18:07 Sep 23, 2024
Jkt 262001
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 51,
Rm. 6200, Silver Spring, MD 20993,
301–796–3600.
SUPPLEMENTARY INFORMATION:
I. Background
The Drug Price Competition and
Patent Term Restoration Act of 1984
(Pub. L. 98–417) and the Generic
Animal Drug and Patent Term
Restoration Act (Pub. L. 100–670)
generally provide that a patent may be
extended for a period of up to 5 years
so long as the patented item (human
drug or biological product, animal drug
product, medical device, food additive,
or color additive) was subject to
regulatory review by FDA before the
item was marketed. Under these acts, a
product’s regulatory review period
forms the basis for determining the
amount of extension an applicant may
receive.
A regulatory review period consists of
two periods of time: a testing phase and
an approval phase. For human drug
products, the testing phase begins when
the exemption to permit the clinical
investigations of the drug becomes
effective and runs until the approval
phase begins. The approval phase starts
with the initial submission of an
application to market the human drug
product and continues until FDA grants
permission to market the drug product.
Although only a portion of a regulatory
review period may count toward the
actual amount of extension that the
Director of USPTO may award (for
example, half the testing phase must be
subtracted as well as any time that may
have occurred before the patent was
issued), FDA’s determination of the
length of a regulatory review period for
a human drug product will include all
of the testing phase and approval phase
as specified in 35 U.S.C. 156(g)(1)(B).
FDA has approved for marketing the
human drug product, QUVIVIQ
(daridorexant hydrochloride) indicated
for the treatment of adult patients with
insomnia characterized by difficulties
with sleep onset and/or sleep
maintenance. Subsequent to this
approval, the USPTO received a patent
term restoration application for
QUVIVIQ (U.S. Patent No. 9,732,075)
from Idorsia Pharmaceuticals Ltd. and
the USPTO requested FDA’s assistance
in determining the patent’s eligibility
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
77869
for patent term restoration. In a letter
dated September 28, 2023, FDA advised
the USPTO that this human drug
product had undergone a regulatory
review period and that the approval of
QUVIVIQ represented the first
permitted commercial marketing or use
of the product. Thereafter, the USPTO
requested that FDA determine the
product’s regulatory review period.
II. Determination of Regulatory Review
Period
FDA has determined that the
applicable regulatory review period for
QUVIVIQ is 2,115 days. Of this time,
1,660 days occurred during the testing
phase of the regulatory review period,
while 455 days occurred during the
approval phase. These periods of time
were derived from the following dates:
1. The date an exemption under section
505(i) of the Federal Food, Drug, and
Cosmetic Act (FD&C Act) (21 U.S.C. 355(i))
became effective: June 24, 2016. FDA has
verified the applicant’s claim that the date
the investigational new drug application
became effective was on June 24, 2016.
2. The date the application was initially
submitted with respect to the human drug
product under section 505 of the FD&C Act:
January 8, 2021. FDA has verified the
applicant’s claim that the new drug
application (NDA) for QUVIVIQ (NDA
214985) was initially submitted on January 8,
2021.
3. The date the application was approved
or the date of issuance of the interim final
rule controlling the drug under section 201(j)
of the Controlled Substances Act: April 7,
2022. FDA has verified the applicant’s claim
that NDA 214985 was approved by FDA on
January 7, 2022. However, the Drug
Enforcement Agency issued an interim final
rule controlling the product under section
201(j) of the Controlled Substances Act on
April 7, 2022.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the USPTO applies several
statutory limitations in its calculations
of the actual period for patent extension.
In its application for patent extension,
this applicant seeks 1,030 days of patent
term extension.
III. Petitions
Anyone with knowledge that any of
the dates as published are incorrect may
submit either electronic or written
comments and, under 21 CFR 60.24, ask
for a redetermination (see DATES).
Furthermore, as specified in § 60.30 (21
CFR 60.30), any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period. To
meet its burden, the petition must
comply with all the requirements of
E:\FR\FM\24SEN1.SGM
24SEN1
77870
Federal Register / Vol. 89, No. 185 / Tuesday, September 24, 2024 / Notices
§ 60.30, including but not limited to:
must be timely (see DATES), must be
filed in accordance with § 10.20, must
contain sufficient facts to merit an FDA
investigation, and must certify that a
true and complete copy of the petition
has been served upon the patent
applicant. (See H. Rept. 857, part 1, 98th
Cong., 2d sess., pp. 41–42, 1984.)
Petitions should be in the format
specified in 21 CFR 10.30.
Submit petitions electronically to
https://www.regulations.gov at Docket
No. FDA–2013–S–0610. Submit written
petitions (two copies are required) to the
Dockets Management Staff (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD
20852.
Dated: September 19, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–21836 Filed 9–23–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Building Interdisciplinary Research
Careers in Women’s Health (BIRCWH)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Building
Interdisciplinary Research Careers in
Women’s Health (BIRCWH) is an
institutional mentored careerdevelopment program designed to
connect junior faculty, known as
BIRCWH Scholars, to senior faculty
mentors with shared interest in
women’s health and sex differences
research. The BIRCWH Annual Meeting
is a gathering of senior and junior
faculty that provides an opportunity to
network and share scientific advances.
DATES: The meeting will be held on
October 1, 2024, from 8 a.m. to 5 p.m.
EDT.
ADDRESSES: The meeting will be in
person; registration is at https://
www.eventbrite.com/e/2024-bircwhannual-meeting-tickets-893884130497.
The meeting is viewable at https://
videocast.nih.gov/watch=55110.
FOR FURTHER INFORMATION CONTACT: For
information concerning this meeting,
visit https://orwh.od.nih.gov/about/
newsroom/events/2024-buildinginterdisciplinary-research-careers-inwomens-health-bircwh-annual-meeting,
or contact Dr. Marquitta White, Senior
Research Program Officer, Careers
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:07 Sep 23, 2024
Jkt 262001
Section, in the Office of Research on
Women’s Health (ORWH), 6707
Democracy Boulevard, Suite 400,
Bethesda, MD 20817, telephone: 301–
402–1770; email: marquitta.white@
nih.gov.
SUPPLEMENTARY INFORMATION: This
notice is in accordance with 42 U.S.C.
287d of the Public Health Service Act,
as amended. Created by the ORWH in
partnership with NIH Institutes,
Centers, and Offices.
This year, the BIRCWH abstracts have
been grouped into nine categories with
the following number of abstracts, from
highest to lowest: Public Health (12),
Reproductive Health (10), Sex and
Gender Differences (9), Health
Disparities (9), Cancer (9), Neuroscience
(8), Clinical Research (7), Basic Research
(6), and Bioengineering/Bioinformatics
(3). The number and quality of abstracts
centered on Public Health and Basic
Research has increased this year,
indicating a growing focus on women’s
health and the influence of biological
sex on health and disease in these
important areas. Specifically, several
abstracts in these categories focus on
maternal morbidity, perinatal health,
and how biological sex and gender
transition impact health and disease.
The meeting will include the 2024 Ruth
L. Kirschstein Memorial Lecture by
Abbey B. Berenson M.D., MMS, Ph.D.,
and the 2024 Legacy of Leadership
Lecture by Nina F. Schor, M.D., Ph.D.
Individuals interested in in-person
attendance can register online at https://
www.eventbrite.com/e/2024-bircwhannual-meeting-tickets-893884130497.
More information about the speakers
and agenda can be found at https://
orwh.od.nih.gov/about/newsroom/
events/2024-building-interdisciplinaryresearch-careers-in-womens-healthbircwh-annual-meeting.
This event is free.
Dated: September 16, 2024.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
[FR Doc. 2024–21717 Filed 9–23–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Public Health
Service (PHS) Applications and PreAward Reporting Requirements (Office
of the Director)
AGENCY:
National Institutes of Health,
HHS.
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
ACTION:
Notice.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Ms. Mikia P. Currie, Program
Analyst, Office of Policy for Extramural
Research Administration, 6705
Rockledge Drive, Suite 350, Bethesda,
Maryland 20892, or call a non-toll-free
number 301–435–0941 or email your
request, including your address to
ProjectClearanceBranch@mail.nih.gov.
Formal requests for additional plans and
instruments must be requested in
writing.
SUPPLEMENTARY INFORMATION: This
proposed information collection was
previously published in the Federal
Register on May 22, 2024, pages 45001–
45003 (89 FR 45001) and allowed 60
days for public comment. No public
comments were received. The purpose
of this notice is to allow an additional
30 days for public comment.
The Office of the Director (OD), Office
of Extramural Research (OER), National
Institutes of Health (NIH), may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid Office of Management
and Budget (OMB) control number.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, NIH has
submitted to OMB a request for review
and approval of the information
collection listed below.
Proposed Collection Title: Public
Health Service (PHS) Applications and
SUMMARY:
E:\FR\FM\24SEN1.SGM
24SEN1
]]>Agencies
[Federal Register Volume 89, Number 185 (Tuesday, September 24, 2024)]
[Notices]
[Pages 77868-77870]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21836]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2023-E-2584]
Determination of Regulatory Review Period for Purposes of Patent
Extension; QUVIVIQ
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) has
determined the regulatory review period for QUVIVIQ and is publishing
this notice of that determination as required by law. FDA has made the
determination because of the submission of an application to the
Director of the U.S. Patent and Trademark Office (USPTO), Department of
Commerce, for the extension of a patent which claims that human drug
product.
DATES: Anyone with knowledge that any of the dates as published (see
SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic
or written comments and ask for a redetermination by November 25, 2024.
Furthermore, any interested person may petition FDA for a determination
regarding whether the applicant for extension acted with due diligence
during the regulatory review period by March 24, 2025. See
``Petitions'' in the SUPPLEMENTARY INFORMATION section for more
information.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of November 25, 2024. Comments
received by mail/hand delivery/courier (for written/paper submissions)
will be considered timely if they are received on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
[[Page 77869]]
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2023-E-2584 for ``Determination of Regulatory Review Period for
Purposes of Patent Extension; QUVIVIQ.'' Received comments, those filed
in a timely manner (see ADDRESSES), will be placed in the docket and,
except for those submitted as ``Confidential Submissions,'' publicly
viewable at https://www.regulations.gov or at the Dockets Management
Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with Sec. 10.20 (21 CFR 10.20) and
other applicable disclosure law. For more information about FDA's
posting of comments to public dockets, see 80 FR 56469, September 18,
2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
51, Rm. 6200, Silver Spring, MD 20993, 301-796-3600.
SUPPLEMENTARY INFORMATION:
I. Background
The Drug Price Competition and Patent Term Restoration Act of 1984
(Pub. L. 98-417) and the Generic Animal Drug and Patent Term
Restoration Act (Pub. L. 100-670) generally provide that a patent may
be extended for a period of up to 5 years so long as the patented item
(human drug or biological product, animal drug product, medical device,
food additive, or color additive) was subject to regulatory review by
FDA before the item was marketed. Under these acts, a product's
regulatory review period forms the basis for determining the amount of
extension an applicant may receive.
A regulatory review period consists of two periods of time: a
testing phase and an approval phase. For human drug products, the
testing phase begins when the exemption to permit the clinical
investigations of the drug becomes effective and runs until the
approval phase begins. The approval phase starts with the initial
submission of an application to market the human drug product and
continues until FDA grants permission to market the drug product.
Although only a portion of a regulatory review period may count toward
the actual amount of extension that the Director of USPTO may award
(for example, half the testing phase must be subtracted as well as any
time that may have occurred before the patent was issued), FDA's
determination of the length of a regulatory review period for a human
drug product will include all of the testing phase and approval phase
as specified in 35 U.S.C. 156(g)(1)(B).
FDA has approved for marketing the human drug product, QUVIVIQ
(daridorexant hydrochloride) indicated for the treatment of adult
patients with insomnia characterized by difficulties with sleep onset
and/or sleep maintenance. Subsequent to this approval, the USPTO
received a patent term restoration application for QUVIVIQ (U.S. Patent
No. 9,732,075) from Idorsia Pharmaceuticals Ltd. and the USPTO
requested FDA's assistance in determining the patent's eligibility for
patent term restoration. In a letter dated September 28, 2023, FDA
advised the USPTO that this human drug product had undergone a
regulatory review period and that the approval of QUVIVIQ represented
the first permitted commercial marketing or use of the product.
Thereafter, the USPTO requested that FDA determine the product's
regulatory review period.
II. Determination of Regulatory Review Period
FDA has determined that the applicable regulatory review period for
QUVIVIQ is 2,115 days. Of this time, 1,660 days occurred during the
testing phase of the regulatory review period, while 455 days occurred
during the approval phase. These periods of time were derived from the
following dates:
1. The date an exemption under section 505(i) of the Federal
Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(i)) became
effective: June 24, 2016. FDA has verified the applicant's claim
that the date the investigational new drug application became
effective was on June 24, 2016.
2. The date the application was initially submitted with respect
to the human drug product under section 505 of the FD&C Act: January
8, 2021. FDA has verified the applicant's claim that the new drug
application (NDA) for QUVIVIQ (NDA 214985) was initially submitted
on January 8, 2021.
3. The date the application was approved or the date of issuance
of the interim final rule controlling the drug under section 201(j)
of the Controlled Substances Act: April 7, 2022. FDA has verified
the applicant's claim that NDA 214985 was approved by FDA on January
7, 2022. However, the Drug Enforcement Agency issued an interim
final rule controlling the product under section 201(j) of the
Controlled Substances Act on April 7, 2022.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the USPTO
applies several statutory limitations in its calculations of the actual
period for patent extension. In its application for patent extension,
this applicant seeks 1,030 days of patent term extension.
III. Petitions
Anyone with knowledge that any of the dates as published are
incorrect may submit either electronic or written comments and, under
21 CFR 60.24, ask for a redetermination (see DATES). Furthermore, as
specified in Sec. 60.30 (21 CFR 60.30), any interested person may
petition FDA for a determination regarding whether the applicant for
extension acted with due diligence during the regulatory review period.
To meet its burden, the petition must comply with all the requirements
of
[[Page 77870]]
Sec. 60.30, including but not limited to: must be timely (see DATES),
must be filed in accordance with Sec. 10.20, must contain sufficient
facts to merit an FDA investigation, and must certify that a true and
complete copy of the petition has been served upon the patent
applicant. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41-42,
1984.) Petitions should be in the format specified in 21 CFR 10.30.
Submit petitions electronically to https://www.regulations.gov at
Docket No. FDA-2013-S-0610. Submit written petitions (two copies are
required) to the Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
Dated: September 19, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-21836 Filed 9-23-24; 8:45 am]
BILLING CODE 4164-01-P
